Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2023-12-12
Target enrollment:
Participant gender:
Summary
A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for
the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)